Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIVIMEC: CWI vs ITM for Cesarean Recovery
NCT05696678Withdrawn
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms). Primary endpoint: Obstetric Quality-of-Recovery-11 Score at 24 hours. Planned start Feb 2023; status: withdrawn.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05696678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696678.